In late 2014, shares of Pain Therapeutics plunged from a high of $4.25 to less than $1.75 after Pfizer ended an agreement to help it develop and market the Remoxy pain drug along with Durect Corporation. Since then, PTIE has been greatly ignored. However, after finding value in the stock, we would recommend it to…
DetailsIf you want to know what’s next for stocks, just follow the money. It seems obvious. Yet few investors do it and so many pay a high price for it. That’s why today’s analysis of the hottest exchange traded fund (ETF) in America reveals one major market event all investors should be getting prepared for…
DetailsOne of the single best biotech stocks to own over the last two months went largely unnoticed after a 49% drop from a high of $3.67. For quite some time, Rigel Pharmaceuticals wasn’t considered anything special. Except for the fact it truly was. In fact, we’ve been so impressed with the stock over the last…
DetailsLast weekend tens of thousands of investors swarmed into Omaha, Nebraska for the Berkshire Hathaway annual. They had good reason to go too. The value of just one idea, one new and different perspective, or an important lesson can easily be worth the cost of the trip many times over. The funny thing is, most…
DetailsFor the first time in history, we now have an FDA-approved treatment for Parkinson’s disease Psychosis. It’s great news for longs and patients that have been suffering from grueling hallucinations associated with PDP. While the FDA has asked for a black box warning due to increased risk of death associated with use in older people,…
DetailsThe Federal Reserve painted itself into a dangerous corner. At the April 2016 meeting, the central bank again left rates as is, offering very little guidance for when they may raise rates again. While Dallas Federal Reserve President, Robert Kaplan, wants to raise interest rates as soon as June or July, that may not be…
DetailsLong time readers know your editor a “cord-cutter.” It’s an exclusive club of about 11 million people who don’t want to pay for hundreds of cable channels they never watch. I’m not a cutting edge tech guy, trend follower, or anything of the sort who had to jump on it though. From my experience, I…
DetailsI realize it sounds pollyannish to say this is a great time to be an investor. That was my first reaction when a longtime friend and colleague — who’s turned me on to more than a handful of 100%+ winners over the years — told me it was. Everywhere you look there’s reason to fear.…
DetailsOne of the best stocks to own over the last few years wasn’t very exciting… It didn’t have a cure for cancer or anything that was revolutionary. Nothing head turning… It’s not as if we uncovered the next Apple or Amazon. But what I did uncover was extreme value, a stock selling for 77% less…
DetailsSelf-driving cars are going to be the future. It’s inevitable, really. They offer everything. Safer. More efficient. Etc. The thing is though, they’re going to be the “car of the future” for a long, long time. It’s not going to be 2020 (which is only four years away now). Or 2030. Maybe 2040 they’ll be…
DetailsIt’s been one of the hottest biotechs we’ve bought over the last five years… Since recommending ACADIA Pharmaceuticals (ACAD) at $1.05 and $1.24 in 2010, we’ve watched the stock soar to $51.99 for gains of 4,851% and 4,093%. Every $1,000 risked is now worth well over $45,000. Every $5,000 risked is now well over $230,000.…
DetailsThe Dow Jones (DJIA) closed above 18,000 for the first time since July 2015. All would seem well for the average investor… or so we think. Unfortunately, the stock market and the economy seem to be moving in opposite directions. For example, even as stock prices rally near historic highs, corporations are defaulting on debt…
Details